Beijing-based Immunochina Pharmaceuticals, a provider of cancer diagnosis and treatment services, has raised about $20.4 million in funding. The investors included Shougang Fund, Sherpa Venture Capital, Peter Thiel, Qingzhe Capital and China Resources Innovative Equity Investment Fund.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: